Almirall, S.A. Overview
Pro stress-test →Almirall is a Spanish pharmaceutical company dedicated to medical dermatology, headquartered in Barcelona and founded in 1944. In 2023, the company generated total revenues of €898.8 million and was the leading European company in medical dermatology. The company operates globally with a specialized focus on dermatological treatments across multiple therapeutic areas.
Strategic Profile
Pro stress-test →In 2014 Almirall divested its respiratory franchise to Astrazeneca, focusing on dermatology, and has pursued strategic acquisitions to expand its dermatology portfolio. Almirall operates a global network with over 1,800 employees, 15 subsidiaries, and distribution in over 100 countries across 5 continents. The company is leveraging AI-driven innovation in drug discovery to strengthen its competitive position in the dermatology space.
Competitive Landscape
Pro stress-test →Key competitors include AbbVie Inc., Pfizer Inc., GSK plc, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd., Galderma, and Amgen Inc. Almirall's competitive advantage lies in its focused geographic leadership in Europe, specialized dermatology expertise, and expanding biologics portfolio within a niche but growing therapeutic segment.
Industry Context
Almirall, S.A. operates in Biopharmaceuticals - Medical Dermatology.
Key facts
Founded: 1944 · Headquarters: Barcelona, Spain · Employees: 2,000+ · Revenue: €990M (2024)